Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

FDA lifts clinical hold on Alnylam Pharmaceuticals' fitusiran

Dec. 18, 2017

First in vivo results for LSD1 inhibitor show promise for the treatment of SCD

Dec. 15, 2017

Vertex enters development agreement with CRISPR Therapeutics for gene-editing treatment

Dec. 14, 2017

Positive first-in-human data for new complement C3 inhibitor AMY-10

Dec. 14, 2017

Principia Biopharma begins clinical studies of PRN-1008 in ITP

Dec. 14, 2017

EMA's CHMP requests additional information for betrixaban MAA

Dec. 13, 2017

Rockefeller University presents novel FXIIa inhibitors

Dec. 12, 2017

CRISPR Therapeutics applies to conduct clinical trial of CTX-001

Dec. 12, 2017

Janssen submits sNDA in U.S. for two new Xarelto indications

Dec. 12, 2017

OG-L002 shows promising in vivo results for the treatment of sickle cell disease

Dec. 11, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...